Literatur
1.
Griesinger F, Eberhardt W, Früh M, et al.: DGHO-Leitlinie «Lungenkarzinom, nicht-kleinzellig (NSCLC)». Stand: Oktober 2012. www.dgho.de.
2.
MacConaill LE: Advancing personalized cancer medicine in lung cancer. Arch Pathol Lab Med 2012;136:1210-1216.
[PubMed]
3.
Molina JR, Yang P, Cassivi SD, et al.: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83: 584-594.
[PubMed]
4.
Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
[PubMed]
5.
Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
[PubMed]
6.
Rosell R, Moran T, Queralt C, et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
[PubMed]
7.
Kwak EL, Bang YJ, Camidge DR, et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
[PubMed]
8.
Topalian SL, Hodi FS, Brahmer JR, et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
[PubMed]
9.
Brahmer JR, Tykodi SS, Chow LQ, et al.: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366: 2455-2465.
[PubMed]
10.
Lawrence MS, Stojanov P, Polak P, et al.: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499: 214-218.
[PubMed]
11.
Topalian SL, Weiner GJ, Pardoll DM: Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-4836.
[PubMed]
12.
Brahmer JR, Horn L, Gandhi L, et al.: Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. J Clin Oncol 2014;32:5s(suppl):abstr 8112.
13.
Kirchner H, Casper J, Gauler T: DGHO-Leitlinie «Nierenzellkarzinom (Hypernephrom)». Stand Februar 2013. www.dgho.de.
14.
Van Poppel H, Ameye F: Chemotherapeutic agents for urologic oncology; in Chapple CR, Steers WD (eds): Practical Urology: Essential Principles and Practice. London, Springer, 2011.
15.
Hutson TE: Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011;16(suppl 2):14-22.
[PubMed]
16.
McDermott DF: Immunotherapy of metastatic renal cell carcinoma. Cancer 2009;115:2298-2305.
[PubMed]
17.
Herbst RS, Gordon MS, Fine GD, et al.: A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 2013;31(suppl):abstr 3000.
18.
Hodi FS, Topalian SL, Brahmer JR, et al.: Survival, efficacy, and long-term safety in patients with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538). European Cancer Congress 2013;abstr 880.
19.
Clinical Science Symposium: «Unleashing the Immune System in Genitourinary Cancers», 2014 ASCO Annual Meeting, 31.05.2014 (Abstracts #5009, #5010, #5012).
20.
Oral Abstract Session: «Genitourinary (Nonprostate) Cancer» 2014, ASCO Annual Meeting, 2.6.2014: (Abstract: #4504).
21.
Motzer RJ, Rini BI, McDermott DF, et al.: Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J Clin Oncol 2014;32:5s(suppl):abstr 5009).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
